Teva Canada's Herzuma (biosimilar- trastuzumab) Receives Health Canada Approval for Multiple Cancer Indications
Shots:
- Health Canada has granted notice of compliance for Teva Canada’s Herzuma for the treatment of early breast cancer (EBC)- metastatic breast cancer (MBC) and metastatic gastric cancer (MGC) in Canada
- The Health Canada NOC is based on efficacy- safety- quality- immunogenicity- PK/PD data from non-clinical and clinical studies- demonstrating that Herzuma and Herceptin has high bio similarity in terms of purity- potency and safety for the three approved indications
- Herzuma is a mAb biosimilar of the reference product- Herceptin targeting ECD of HER2 receptor and has received MFDS- EC and the FDA’s approval in Jan’2014- Feb’2018 and Dec’2018 respectively
Click here to read full press release/ article | Ref: Newswire Canada | Image: ImgBin
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com